Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS115644 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Arm 1 |
| 2 | EXPERIMENTAL | Arm 2 |
| 3 | EXPERIMENTAL | Arm 3 |
| 4 | EXPERIMENTAL | Arm 4 |
| 5 | EXPERIMENTAL | Arm 5 |
| Name | Type | Description |
|---|---|---|
| INS115644 Ophthalmic Solution | DRUG | One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days |
| Placebo | DRUG | One drop of placebo in each eye every 12 hours for three days |
Inclusion Criteria: * Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma * Have best corrected visual acuity in both eyes of at least +0.5 or better * Have normal endothelial cell counts and morphology Exclusion Criteria: * Are diagnosed with closed angle glauc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
INS115644 is an investigational small molecule being developed for the treatment of ocular hypertension and open angle glaucoma. It is formulated as an ophthalmic solution and is currently in Phase 1 clinical development.
INS115644 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK.
INS115644 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it is not yet approved by the FDA. The drug remains investigational and is still undergoing clinical evaluation.
INS115644 has been studied in one completed Phase 1 clinical trial, identified as NCT00443924. This trial evaluated the ophthalmic solution in subjects with ocular hypertension or open angle glaucoma and enrolled 56 participants.
INS115644 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. Further clinical development and regulatory review would be required before any approval could be considered.